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Previous studies showed the relevance of the cytotoxic T-cell precursor (CTLp) frequency
assay for prediction of the outcome of HLA mismatched hematopoietic cell transplanta-
tion (HCT). Recently, it has been shown that HLA-C cell surface expression is correlated
with virus specific cytotoxicT-cell responses and viremia control in HIV patients.The aim of
the current study was to investigate the association between HLA-C antigen expression
and the CTLp frequency to the mismatched HLA-C antigen. In total 115 recipient–donor
pairs, for whom a successful CTLp assay was performed, were evaluated for this pilot
study. All donor–recipient pairs were matched at 9/10 alleles with a single mismatch at the
HLA-C locus. Antigen expression level of the mismatched HLA-C allele for each recipient
and donor was based on the mean fluorescence intensity (MFI) values as described by
Apps et al. (1). The cell surface expression of recipient’s mismatched HLA-C antigen was
significantly lower among CTLp negative (n=59) compared to CTLp positive (n=56) pairs
(154 and 193 MFI units, respectively, p=0.0031). This difference was more pronounced
in donor–recipient pairs that were mismatched for amino-acid residue-116 located in the
groove of the HLA-C antigen, suggesting that the importance of peptide binding in the
allo-recognition. Furthermore, in the particular case of low expression of the recipient mis-
matched HLA-C antigen (MFI<115), CTLp reactivity depended on HLA-C expression level
in the donor, the median MFI of donor’s mismatched HLA-C antigen was 114 in CTLp
negative cases (n=26), while in CTLp positive cases (n=15) the median MFI of donor’s
HLA-C antigen was 193 (p=0.0093). We conclude that the expression level of the donor
and recipient mismatched HLA-C antigens affect CTLp outcome. HLA-C antigen expres-
sion levels in combination with the CTLp assay may prove useful for the prediction of the
clinical outcome of HLA-C mismatched HCT.
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INTRODUCTION
Matching of HLA-C alleles between donor and recipient is associ-
ated with favorable outcome in hematopoietic cell transplantation
(HCT) (2) and in cord blood transplantation (3). However, recent
data show that the immunogenicity of HLA Class I mismatches
may vary. Some Class I mismatches lead to a strong allo-immune
response associated with severe clinical complications such as graft
versus host disease (GvHD), whereas others are associated with
better clinical results due to lack of a detrimental allo-immune
response (4, 5). Previous studies showed the relevance of the
cytotoxic T-cell precursor (CTLp) frequency assay for predicting
outcome of HLA mismatched HCT (6). Patient survival is sig-
nificantly better if no cytotoxic T-cells (CTLs) are present in the
donor versus the recipient’s HLA mismatched antigen, compared
to a donor–recipient combination with a positive CTLp test (7).
Several approaches for characterizing differential allo-reactivity
amongst HLA mismatches have been suggested, such as com-
patibility in killer-immunoglobulin receptors (KIR) or at specific
amino-acid residues. However, none of these concepts has been
able to provide a coherent reliable prediction of allo-reactivity
and its clinical consequence in HCT.
Recently, it has been shown that HLA-C cell surface expres-
sion is correlated with virus specific cytotoxic T-cell responses
and viremia control in HIV patients (1, 8–10) as well as in pro-
tection against Crohn disease (CD) (1, 10). Apps et al. (1) have
described a method for coherent quantitative evaluation of HLA-C
cell surface expression by measurement of the mean fluorescence
intensity (MFI) for every serologically defined HLA-C antigen.
The aim of the present study was to investigate the possible asso-
ciation between HLA-C antigen cell surface expression and the
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CTLp assay outcome. As the CTLp assay is technically very diffi-
cult, these studies may lead to an alternative and easier approach
to predict T-cell mediated allo-reactivity, thus, facilitating donor
selection for HCT.
MATERIALS AND METHODS
PATIENTS AND DONORS
We studied 115 recipient–donor pairs registered by the Europ-
donor Foundation, for whom a successful CTLp assay was per-
formed (114 unrelated, 1 related). Patients were adults and chil-
dren referred for HCT in one of three Dutch transplant centers:
Leiden University Medical Center (LUMC), Erasmus Medical Cen-
ter – Daniel den Hoed, and University Medical Centre Utrecht
(UMCU) – Wilhelmina Children’s Hospital. Patients were diag-
nosed with either malignant or non-malignant diseases. The unre-
lated donors were from Europdonor Foundation or from interna-
tional donor registries. All donor–recipient pairs were matched at
9/10 alleles at allele-level resolution with a single allele or antigen
mismatch at the HLA-C locus. All testings were performed as part
of routine clinical work-up in preparation for donor selection for
allogeneic transplantation. The data for this study were collected
retrospectively and anonymously from laboratory records.
HLA GENOTYPING AND CTLp ASSAY
All donors and patients were typed for HLA-A, -B, -C, -DRB1,
and -DQB1 at allelic resolution as described previously (11). In
brief, polymerase chain reaction sequence specific primer and
sequence based typing were used. The CTLp assays were per-
formed as described by Zhang et al. (12), with minor modifications
as described by Oudshoorn et al. (11). CTLp assays were per-
formed in the graft versus host (GvH) direction: donor cells were
used as responder cells and patient cells as stimulator and target
cells. A negative CTLp result was defined as ≤1 recipient-specific
CTL per 106 peripheral blood lymphocytes.
HLA-C MATCH CHARACTERISTICS
Antigen expression level of HLA-C alleles was based on the MFI
values for each Cw serologic equivalent as described by Apps et al.
(1). Alignment of amino-acid sequences of donor and recipient
HLA-C alleles for determination of position-116 matching was
performed using the Immuno Polymorphism Database website of
the European Bioinformatics Institute (13). KIR-ligand compat-
ibility prediction was based on donor and recipient HLA-B and
HLA-C allelic resolution typing using the KIR-ligand calculator
provided in the Immuno Polymorphism Database website of the
European Bioinformatics Institute (13). As described by Ruggeri
et al. (14), KIR-ligand compatibility was defined as presence in
recipients of donor Class I allele antigen groups recognized by
KIRs, and incompatibility was defined as absence in the recipient
of donor Class I antigen groups recognized by KIRs.
STATISTICAL ANALYSIS
Comparison of independent MFI values between two groups was
performed using the Mann–Whitney U (MWU) test, as this para-
meter is associated with HLA-C allele type and therefore not
normally distributed.
For the univariate and multivariate logistic regression analyses,
C antigen cell surface expression levels of the mismatched HLA-C
allele, as expressed in predicted MFI units based on previous deter-
mination of mean expression of each allele, were first calculated as
a discrete numerical variable and in addition were dichotomized
into a binary variable of high- (MFI> 200) or low- (MFI≤ 115)
expression levels. In regard to the discrete parameters, the change
in OR shown for HLA-C expression represents an increase of 50
MFI expression units, taking the OR determined for an increase of
a single unit and converting it by following: e(ln(OR)*50). Recipient
and donor mismatched C allele MFI levels were combined together
for the univariate logistic regression analysis in the following man-
ner: (1) A discrete numerical interaction variable calculated by
multiplication of the two discrete numerical variables. (2) A binary
variable: category 0 is of donor–recipient pairs where both HLA-
C mismatched alleles are low (MFI≤ 115) and the category 1 is
of pairs where at least one of the HLA-C mismatched alleles is
high (MFI> 200). Multivariate logistic regression analysis, based
on all parameters that were found to be statistically significant
in the univariate analysis, was performed by stepwise elimination
based on the Wald statistic. Statistical significance was declared
at p< 0.05. All analyses were performed using SPSS 20.0.0 (IBM
SPSS Corporation, Chicago, IL, USA).
RESULTS
ASSOCIATION OF RECIPIENT AND DONOR C ANTIGEN EXPRESSION
WITH CTLp OUTCOME
Overall, median MFI of recipient’s mismatched HLA-C antigen
expression was significantly lower among CTLp negative (n= 59)
compared to CTLp positive (n= 56) pairs (154 and 193, respec-
tively, p= 0.0031, MWU test) (see Figure 1). The MFI level of the
donor’s mismatched HLA-C antigen was similar in CTLp negative
or positive pairs (164 and 170, respectively, p= 0.081, MWU test).
FIGURE 1 | Association of recipient mismatched C antigen cell surface
expression level with CTLp result. Median MFI of recipient’s mismatched
HLA-C antigen cell surface expression was significantly lower among CTLp
negative compared to CTLp positive pairs (p=0.0031, MWU test).
Horizontal line represents median MFI, box plot represents MFI values
between the 25th and 75th percentiles, and thin whiskers represent range.
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Particular cases of low-recipient HLA-C expression
However, in the particular cases where recipient HLA-C expression
was low (C*07 or C*03; MFI< 115), CTLp reactivity appeared to
depend on the HLA-C expression level in the donor (as depicted
in Figure 2). In CTLp negative cases (n= 26), the median MFI of
donor’s mismatched HLA-C antigen was 114, while in CTLp posi-
tive cases (n= 15), the median MFI of donor’s HLA-C antigen was
193 (p= 0.0093, MWU test).
Particular cases of high-recipient HLA-C expression
On the other hand, in particular, cases where the recipient HLA-C
was high (C*06, C*18, C*01, and C*14; MFI≥ 225) no correlation
between the donor’s HLA-C antigen expression and the CTLp
result was observed (data not shown).
DONOR–RECIPIENT HLA-C MATCH CHARACTERISTICS
Next, the association between HLA-C expression and CTLp
allo-reactivity was analyzed taking into consideration previously
described HLA-C match characteristics, which affect either CTLp
or clinical outcome:
HLA-C*03:03–C*03:04 as a permissible mismatch
Previous publications (5, 11) have identified the combination of
C*03:03–C*03:04 as a permissible mismatch that is better toler-
ated than other HLA mismatches. This is likely due to the fact that
the amino-acid substitution in residue 91 (located in a loop con-
necting the α1 and α2 domains) is located at a place on the HLA-C
molecule that is not recognized by the T-cell receptor (TCR). In
our study cohort, nine pairs presented a mismatch of C*03:03–
C*03:04 alleles between the donor and recipient. All of these nine
pairs resulted in a negative CTLp. When excluding these pairs from
the overall analysis, the difference between the medians of CTLp
negative (n= 50) and CTLp positive (n= 56) remains significant
(159 and 193, respectively, p= 0.0173, MWU test).
Position-116 match
Several publications have indicated that matching the amino-acid
at position-116 in the HLA-C protein confers protection against
the risk for acute GvHD (4, 15). In the current study cohort, we did
not find a significant association between matching at position-
116 and CTLp result. Positive CTLp allo-reactivity was detected in
17 of the 37 position-116 matched pairs (46%), which is compara-
ble to 39 of the 78 position-116 mismatched pairs (50%) (p= 0.7,
Fisher’s exact test).
However, the median MFI of the recipient’s mismatched
HLA-C antigen where position-116 was mismatched (187, n= 78)
was significantly higher than in cases in which position-116 was
matched (114, n= 37) (p< 0.001, MWU test). Furthermore, the
association between high-HLA-C cell surface antigen expression
of the recipient’s mismatched allele and a positive CTLp was
augmented in position-116 mismatched pairs, where the median
recipient MFI among CTLp positive pairs (200, n= 39) was
significantly higher than in CTLp negative pairs (164, n= 39)
(p= 0.0030, MWU test; Figure 3). No significant difference in
MFI levels between CTLp positive and negative pairs was identi-
fied among pairs that were matched in position-116 (median 114
in both groups, p= 0.411, MWU test).
FIGURE 2 | Association of donor mismatched C antigen cell surface
expression with CTLp result in cases where the recipient’s antigen is of
low expression (<115). The median MFI of the donor’s mismatched HLA-C
cell surface expression level was lower in CTLp negative cases than in CTLp
positive cases (p=0.0093, MWU test) among pairs where the recipient’s
HLA-C expression level of the mismatched allele was low (MFI<115).
Horizontal line represents median MFI, box plot represents MFI values
between the 25th and 75th percentiles, and thin whiskers represent range.
NK cell allo-reactivity
The compatibility between KIR ligands on donor and recipient
cells expressing HLA-B and HLA-C antigens has been proposed as
a key parameter in evaluating NK cell allo-reactivity (14, 16). KIR-
ligand compatibility has been shown to be a prognostic factor in
the clinical outcome after HCT (17, 18), and can possibly be a key
component in the prognosis of HCT from an HLA-C mismatched
donor, particularly given the primary role of HLA-C as ligands
for KIR.
In our study, we found no correlation between KIR-ligand
compatibility and CTLp allo-reactivity. CTLp allo-reactivity was
detected in 44 of the 90 (49%) donor–recipient pairs that were
KIR-ligand compatible and similarly in 12 of the 25 (48%) donor–
recipient pairs that were KIR-ligand incompatible (p= 1, Fisher’s
exact test). MFI values of the recipient and of the donor mis-
matched HLA-C antigens were not associated with KIR-ligand
compatibility/incompatibility between the donor and the recipi-
ent (recipient median MFI 164 and 180 in KIR-ligand compatible
and KIR-ligand incompatible, respectively, p= 0.424, MWU test;
donor median MFI 164 in both cases). Thus, we did not find
any relevance of donor–recipient KIR-ligand compatibility in the
association between HLA-C antigen MFI levels and CTLp results.
UNIVARIATE LOGISTIC REGRESSION ANALYSIS
Table 1 describes the results of a univariate logistic regression
analysis to test whether CTLp outcome can be predicted by the
studied variables. The recipient’s mismatched HLA-C antigen cell
surface expression level as expressed in MFI units was predictive of
CTLp outcome, both when calculated as a discrete numeric or as a
binary variable. Donor HLA-C antigen cell surface expression level
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FIGURE 3 | Association of recipient C antigen cell surface expression
level with CTLp result is only significant in donor–recipient pairs that
are mismatched at amino-acid position-116. Median recipient mismatched
HLA-C MFI among CTLp positive pairs was significantly higher than in CTLp
negative pairs among pairs that were mismatched at position-116 (p=0.003,
MWU test; left panel). No significant MFI level difference between CTLp
positive and negative pairs was identified in cases where position-116 was
matched (right panel). Horizontal line represents median MFI, box plot
represents MFI values between the 25th and 75th percentiles, and thin
whiskers represent range.
almost reached statistical significance for prediction of CTLp out-
come when calculated as a discrete numeric variable, and reached
significance when considered as a binary variable based on alleles
of extreme high- (MFI> 200) and low- (MFI≤ 115) expression
levels. Furthermore, we found that the interaction variable prod-
uct of the HLA-C antigen MFI levels of the donor and recipient is
significantly predictive of CTLp result. CTLp is 10-fold more likely
to be negative in cases where both HLA-C mismatched alleles are
of low expression.
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS
Table 2 describes the results of a multivariate logistic regression
analysis to test whether CTLp outcome can be predicted by the
studied variables. In a model based on discrete numerical variables,
we found that the cell surface expression level of the recipient and
donor mismatched HLA-C alleles, both separately and in com-
bination, are independent predictors of CTLp result. In a model
of binary variables only the combined donor–recipient parameter
was predictive after stepwise elimination.
DISCUSSION
RATIONALE FOR THE STUDY
Multiple publications have reported that the CTLp frequency assay
is able to predict clinical outcome of HCT (7, 19–21), which is the
reason why this assay is incorporated in the clinical decision mak-
ing of donor selection in several Dutch transplant centers (6). The
CTLp assay quantifies the frequency of donor CTLp’s capable of
responding to mismatched HLA Class I antigens presented on the
recipient’s cells. The CTLp response against non-self HLA Class I
antigens is dependent on physical engagement between the allo-
antigen and the cytotoxic T-cell (22), although the exact mode of
recognition is not yet understood to a degree that would allow
prediction of CTLp allo-reactivity (23). Clearly, the presence of
a mismatched Class I antigen on the surface of the target cell is
essential for a positive CTLp response.
Cell surface expression of HLA-C antigens is regulated by inter-
play of genetic and epi-genetic factors (24, 25). Differential expres-
sion of HLA-C is notably associated with clinical ramifications
such as HIV control and risk of CD (1, 10). Recently, Apps et al. (1)
determined the mean expression levels for each two-digit HLA-C
allotype and showed a direct genetic influence of HLA-C anti-
gen expression level on the course of HIV infection. The authors
demonstrated that HIV peptides presented by highly expressed
HLA-C alleles were more likely to elicit CTL responses in com-
parison to low-expressed HLA-C allotypes even when presenting
the same peptides. These results suggest that increased HLA-
C expression can intensify a CTL-mediated immune response,
consequently leading to enhanced protection in HIV infection.
The rationale for the current study was to investigate whether
cell surface expression levels of HLA-C alleles can assist in predict-
ing CTLp allo-reactivity, as a component of the donor selection
process for patients who do not have a fully HLA-matched donor.
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Table 1 | Univariate logistic regression analysis for prediction of CTLp
outcome.
Odds
ratio
95% confidence
interval
p
DISCRETE NUMERICAL VARIABLES (n=115)
Patient mismatched HLA-C MFI 1.759 1.199–2.580 0.004
Donor mismatched HLA-C MFI 1.384 0.987–1.939 0.059
Interaction variable:
recipient×donor HLA-C MFI
1.002 1.001–1.003 0.008
Shared HLA-C allele MFI 1.012 0.657–1.559 0.957
BINARY VARIABLES
Patient mismatched HLA-C MFI
(n=68)
2.947 1.077–8.066 0.035
Donor mismatched HLA-C MFI
(n=74)
2.923 1.126–7.585 0.027
Combined: recipient and donor
HLA-C MFI (n=41)
10.400 1.928–56.102 0.006
Shared HLA-C allele MFI (n=75) 1.277 0.354–4.613 0.709
Amino-acid position-116 mismatch
(n=115)
1,176 0.537–2.577 0.685
KIR-ligand incompatibility (n=115) 0.965 0.398–2.343 0.937
MFI was calculated as discrete numerical variable, as described by Apps et al.
(1) or dichotomized as a binary variable based on the extreme high- and low-
expression mismatches. In regard to the discrete parameters, the change in OR
shown for HLA-C expression represents an increase of 50 MFI expression units.
Table 2 | Multivariate logistic regression analysis for prediction of
CTLp outcome.
Odds
ratio
95% confidence
interval
p
MODEL I: DISCRETE NUMERICAL VARIABLES (n=115)
Patient mismatched HLA-C MFI 7.889 1.987–31.324 0.003
Donor mismatched HLA-C MFI 6.339 1.594–25.202 0.009
Interaction variable:
recipient×donor HLA-C MFI
0.991 0.984–0.999 0.020
MODEL II: BINARY VARIABLE (n=41)
Combined: recipient and donor
HLA-C MFI
10.400 1.928–56.102 0.006
MFI was calculated as discrete numerical variable, as described by Apps et al.
(1) or dichotomized as a binary variable based on the extreme high- and low-
expression cases. In regard to the discrete model, the change in OR shown for
HLA-C expression represents an increase of 50 MFI expression units.
RECIPIENT HLA-C EXPRESSION LEVEL
In the current study, we found that CTLp allo-reactivity is asso-
ciated with the cell surface expression of the mismatched HLA-C
antigens of the recipient. The presence of HLA-C antigens that are
highly expressed on the surface of recipient cells was significantly
correlated with a higher frequency of alloreactive CTLp. Moreover,
logistic regression analysis showed that recipient HLA-C antigen
MFI is a significant predictor of positive CTLp. This result is
in agreement with the preceding publications reporting stronger
CTL responses in the context of high-HLA antigen expression (26,
27) in HIV patients. Our study is the first to report the associa-
tion between CTLp assay outcome and the genetic predisposition
for HLA-C cell surface expression levels in HCT recipient–donor
pairs.
Our findings are significant at a population level analysis of a
heterogeneous group of 115 patient–donor pairs in spite of par-
tial overlap between the MFI ranges of the studied groups. Thus,
we assume that the significance of CTLp and antigen expres-
sion associations will be even more pronounced in our future
research, upon prospective analysis of both the expression of HLA-
C and CTLp frequency in specific patients and in their potential
prospective donors.
DONOR–RECIPIENT MATCHING AT RESIDUE-116 IN THE HLA-C
ANTIGEN
Several publications have shown that a mismatch between donor
and recipient at amino-acid position-116 of the HLA-C protein is
associated with inferior clinical outcome in HCT, namely, higher
incidence of GvHD (4, 15, 28). Our group has demonstrated
that CTLp assay outcome is also associated with donor–recipient
matching at position-116 (11, 23). Residue-116 is located in the F-
pocket of the peptide binding groove of the HLA Class I molecule
(22). The amino-acid at position-116 does not interact directly
with the TCR, but rather, affects peptide binding to the HLA
molecule. Therefore, the pronounced allo-immunogenicity of a
mismatch at position-116 is likely to be due to presentation of
foreign peptides to the TCR.
In the current study, the association between CTLp result
and recipient HLA-C cell surface expression level was more pro-
nounced in donor–recipient pairs that are mismatched for the
amino-acid at position-116 of the HLA-C antigen. The current
findings demonstrate that allo-reactivity as expressed and mea-
sured by CTLp frequency is multi-factorial. CTLp responsiveness
is determined by the allotype of the recipient’s HLA-C antigen
together with the identity of the peptide presented in the peptide
binding groove of the allo-antigen.
Donor–recipient KIR-ligand compatibility did not affect the
association between CTLp outcome and HLA-C expression levels.
This finding confirms the conclusions of previous publications
that found of no association between KIR-ligand compatibility
and CTLp allo-reactivity (11, 23).
DONOR HLA-C EXPRESSION LEVEL
We also identified an association between the HLA-C cell sur-
face expression level on the donor cells and the CTLp assay
result in donor–recipient pairs where the recipient’s mismatched
HLA-C antigen expression is low. The donor HLA-C MFI was a
significant variable for prediction of CTLp outcome in logistic
regression analysis, both independently and as an interaction vari-
able together with the recipient MFI. Furthermore, we found that
when both donor and recipient carry a mismatched HLA-C allele
of low-cell surface expression, the likelihood of a negative CTLp
result is 10-fold more likely than in a situation where one of the
mismatched alleles is of high expression.
This seems surprising, as donor HLA antigens do not directly
participate in the CTL response against mismatched recipient
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antigens. We hypothesize that the association between the donor
HLA-C cell surface expression level and the CTLp allo-response
is a result of differences in thymic T-cell selection and its impact
on the TCR repertoire on donor cells. This hypothesis is in line
with previous findings by Zemmour et al. (29), who also sug-
gested that the HLA-C antigen trait of low expression has a unique
impact on thymic T-cell selection. Also, more recent publications
have pointed at the possible relationship between the cell surface
expression level of HLA-C antigens and thymic T-cell selection and
the consequent HIV viremia control by HLA-C restricted T-cells
(30–32). Low expression of HLA-C antigens in the thymus may
affect the positive and negative selection and as a consequence,
influence the repertoire and TCR avidity of mature T-cells. This
hypothesis remains to be confirmed.
SUMMARY AND FUTURE DIRECTIONS
The present study shows that there is a significant association
between cell surface expression levels of HLA-C alleles and CTLp
allo-reactivity. Based on their genetically predisposed expression
levels, both recipient and donor mismatched HLA-C alleles can
contribute to prediction of GvH allo-reactivity. Prediction of
allo-reactivity is of importance for the selection of optimal HLA
mismatched donors for patients in need of HCT who do not have
a matched donor. Future studies will aim at the validation of our
findings with clinical data of HCT in order to establish the use-
fulness of incorporating HLA-C expression levels together with
CTLp results for prediction of GvH allo-reactivity.
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